CSL Ltd Annual Report 2021

KCENTRA ® (4 factor prothrombin complex concentrate) recorded sales growth of 7% 1 , a solid result given its demand profile was tempered by the COVID-19 pandemic and the resulting reduction in elective procedures and incidents of trauma. Growth in the specialty portfolio was offset by lower wound healing product sales in Japan and a decline in ZEMAIRA ® (alpha-1 proteinase inhibitor) which experienced supply interruptions at our Kankakee facility in the US. Haemophilia product sales of US$1,107 million declined 4% 1 . The haemophilia portfolio was impacted by reduced doctor visits and patient consultations arising from reduced social mobility due to the COVID-19 pandemic. IDELVION ® , CSL Behring’s novel long-acting recombinant factor IX product, achievedmodest growth of 2% 1 and remained the market leader for the treatment of haemophilia B patients. The haemophilia A market has been competitive resulting in sales declines for AFSTYLA ® , a novel recombinant factor VIII product, and plasma-derived products. Albumin sales of US$1,071 million, up 61% 1 . The company’s new distribution model in China has now been fully operational for 12 months with sales reflecting a more normalized level. Plasma collections , an important rawmaterial, has been adversely impacted by the COVID-19 pandemic. Plasma collection centres remained operational, however, stay at home orders and extended lockdowns restricted the movement of donors and influenced the company’s ability to collect plasma. Consequently, collection volume has reduced and the cost of collection increased, in particular donor compensation. A number of targeted initiatives have been introduced resulting in an improvement in the volume of plasma collected. Seqirus Total revenue of $1,736 million, up 30% 1 driven by strong growth in seasonal influenza vaccines of 41%. Governments around the world have sought to vaccinate their populations against influenza, thereby easing the burden on health care systems that are already under pressure from COVID-19. This has seen strong demand for influenza vaccines across the industry. In addition, there has been an ongoing shift towards Seqirus’ differentiated product portfolio, in particular FLUAD ® and FLUCELVAX ® . CSL Limited Annual Report 2020/21 19